Sites / Tyler Research Institute
Is this you?

Request access for Tyler Research Institute with your @tylerresearchinstitute.com work email. Intera will contact you to verify and set up your account — nothing auto-publishes.

Request account

Tyler Research Institute

Unclaimed profile

Independent Site · Tyler, Texas · ~1 sites

Intera lens
ICP 6Lift (cardio sample) 0.09Recruit soph 0.29
Quality Scorecard (1–100)
Overall80Recruit62Ops88Sponsor88Ther84

Performance (observed)

Historical trials
447
Completed
263
Terminated/Withdrawn
54
Completion rate
83%
Active now
115
Phase 2
162
Phase 3
231
Realized enrollment
414,304
First study year
1994
Years active
32
Match confidence
low
Enrollment velocity (inf)
12,947

Therapeutic

Areas
Gastroenterology, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Specialties
Crohn's Disease, Ulcerative Colitis (Inflammatory bowel disease)
Breadth (conditions)
385
States
Texas

Recruitment (web observed)

Recruitment pages
Yes
Advertises recruitment
Yes
SEO
Y - website with trial information
Capability notes
Established - 21 recruiting trials, focused on IBD research

Relationships

Sponsors
AbbVie; Pfizer; Hoffmann-La Roche; Novartis Pharmaceuticals; Eli Lilly and Company; Takeda
CROs
Acrotech Biopharma Inc.; ICON plc; Medpace, Inc.; PPD, Part of Thermo Fisher Scientific; Teva Branded Pharmaceutical Products R&D LLC
Owner / parent
Iterative Health
Expansion
Y - 20+ years established; specialty-focused continuity

Capacity & people

Investigators
Coordinators
CEO
Aaron DuVall, M.D.
VP Clinical Ops
Unknown
VP Site Ops
Unknown
VP Recruitment
Unknown
Emails
Aaron.duvall@iterativehealth.com; Rachel.hannah@iterativehealth.com

Tech & DCT

CTMS
Unknown (uses Veeva CTV platform)
eSource
Yes
Builds tech
Unknown
Tech stack
Unknown
Recruiting visible
Y

Notes

21 recruiting trials across 1 location(s), states: Texas. Team of 20+ healthcare professionals with 20+ years experience focused on IBD (Crohn's and Ulcerative Colitis). Location: 1720 South Beckham, Tyler, TX. Mission to achieve long-term deep remission for IBD patients through clinical research. Niche specialty focus.

Recommendation features (sample indication)

Ind fit 0.12Liftability 0.09Overall80

FUTURE MOAT: absolute enrollment rates, funnel CPR, measured SSU, screen-fail reasons.